CMN Weekly (28 March 2025) - Your Weekly CRISPR...
CMN Weekly
Mar. 28, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
iECURE
Company Type: Therapeutic development
Main focus: Developing in vivo gene insertion therapies to treat liver diseases
Company stage: Clinical
Diseases: “Loss of function” liver disorders
Genome-editing tool: ARCUS® nuclease
Funding stage: Series A
Location: Blue Bell, Philadelphia, USA
Website: https://iecure.com/
Pipeline: https://iecure.com/programs/#pipeline
Partners: University of Pennsylvania
iECURE’s approach to gene editing for its initial programmes, including a rare liver disorder known as OTC deficiency, relies on the delivery of twin adeno-associated virus (AAV) capsids carrying different payloads. iECURE has licensed the ARCUS nuclease for GTP-506 from Precision BioSciences. GTP-506 comprises two vectors, an ARCUS® nuclease vector (GTP-506A) targeting gene editing in the well-characterised PCSK9 gene locus and a therapeutic donor vector (GTP-506D) that inserts the OTC gene to provide the desired genetic correction. The cut in the PCSK9 site serves as the insertion site for the therapeutic gene, providing a potential path to permanent expression of a healthy gene.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
